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Abstract
TGF-β plays an important role in the genesis and progression of pulmonary fibrosis. We sought to
determine the role of mononuclear phagocytes in the activation of TGF-β and found that freshly
isolated peripheral blood monocytes spontaneously released TGF-β. Stimulating these monocytes
with GM-CSF or LPS, but not MCSF, augmented the activation of TGF-β. In human monocytes, the
free thiol compounds DTT and NAC decreased the activity of TGF-β, without affecting TGF-β
mRNA transcription. Both NAC and DTT lessened the biological activity of recombinant active
TGF-β in a cell-free system. We found that NAC and DTT reduced dimeric active TGF-β from a
25 kDa protein to 12.5 kDa inactive monomer. This conversion was reversed using the oxidizing
agent diamide. Diamide also restored biological activity to NAC or DTT-treated TGF-β. Reduction
of TGF-β to monomers could competitively inhibit active dimeric TGF-β and block intracellular
signaling events. Our observations suggest that modulation of the oxidative state of TGF-β may be
a novel therapeutic approach for patients with pulmonary fibrosis.
Background
TGF-β is a conserved multi-functional growth factor and is
biologically active in femtomolar concentrations [1]. The
effects of TGF-β are diverse and include the modulation of
cell growth and differentiation, suppression of immune
responsiveness, and induction of extracellular matrix pro-
duction [1]. There are three isoforms of TGF-β (TGF-β1,
TGF-β2 and TGF-β3) expressed in humans which are pro-
duced by a variety of cells with platelets being a major
source. In this study, we will focus on TGF-β1 which will
be referred to as TGF-β.
TGF-β is secreted as an inactive latent molecule that is
bound non-covalently with its accessory molecule latency
associated peptide (LAP)[2]. TGF-β and LAP are derived
from the same gene then post-translationally modified.
The TGF-β and LAP monomers form homodimers, which
join together to form the latent TGF-β heterotetramer (L-
TGF-β) or small latent complex. Secreted as L-TGF-β, TGF-
β must dissociate from LAP to be biologically active [3],
which is achieved in vivo by molecules such as throm-
bospondin-1[4], plasmin [5], and the epithelial cell
integrin αvβ6[6]. Once released from LAP, active TGF-β
exists as an intensely hydrophobic homodimeric protein
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disulfide bond [7].
TGF-β exerts its biologic impact through binding and acti-
vation of type I and type II TGF-β serine/threonine kinase
receptors (TGF-βR-I, and TGF-βR-II)[8]. TGF-β is thought
to first bind to type II, which then heterodimerizes with
type I. Upon crosslinking of the receptor subunits, type II
phosphorylates serine and threonine residues located in
conserved GS cytoplasmic domain of type I receptor
resulting in a conformational change of type I and subse-
quent activation of signaling pathways [9]. An accessory
receptor termed type III, does not signal, but is thought to
enhance the association between type I and type II [10].
Ultimately, the signals generated by the TGF-β receptors
are relayed to the nucleus by the Smads transcription fac-
tors [11].
TGF-β1 is the most prevalent isoform found in human
pulmonary fibrotic diseases [12]. In pulmonary fibrosis,
collagen-rich connective tissue is inexorably deposited in
the lung, interrupting gas exchange. In animal models of
pulmonary fibrosis, blocking the binding or function of
TGF-β1 with antibodies, [13] or soluble receptors, [14]
reduces fibrosis. Furthermore, over-expressing the antago-
nistic Smad-7 has the same effect as blocking active TGF-
β and underscores the role of TGF-β on disease models of
fibrosis [15].
The importance of TGF-β1 in fibrotic diseases does not
appear to be limited to animal models, as increased levels
of biologically active TGF-β1 are found in BAL fluid from
patients with fibrotic lung diseases [16]. Moreover, BAL
effluents from patients with pulmonary fibrosis demon-
strate an overabundance of younger, recently recruited
monocyte/macrophages to the lung [17]. These observa-
tions suggest a potential relationship between mononu-
clear phagocytes, TGF-β1 activation, and fibrosis.
It had been previously reported that endothelial cells
secrete TGF-β1, and that the cytokine activity is reduced
when reacted with thiols [18]. In addition, the free thiol
compound N-acetylcysteine (NAC) can modulate the
anti-proliferative activity of TGF-β1 [19] and decrease col-
lagen accumulation in the bleomycin-induced mouse
model of pulmonary fibrosis [20]. We sought to deter-
mine if thiol compounds affected monocyte activation of
TGF-β, and if the effect could be measured in a cell free
system. We found that human monocytes spontaneously
produced TGF-β. The growth factor GM-CSF and LPS each
promoted TGF-β activation in human monocytes. NAC
and DTT reduced the activity of TGF-β produced by
human monocytes, but did not suppress its gene tran-
scription. In a cell-free system, DTT and NAC also blocked
the biological activity of purified active TGF-β by creating
TGF-β monomers. These monomers competitively inhib-
ited the biological effects of active human TGF-β in vitro
as detected by Smad phosphorylation and the TGF-β sen-
sitive luciferase reporter assay. Therefore, modulation of
the oxidative state of TGF-β may be a potential therapy for
patients with pulmonary fibrosis.
Methods
Materials
Human recombinant TGF-β1, purified human active TGF-
β1, and recombinant human latent TGF-β1 were pur-
chased from R&D Systems (Minneapolis, MN). Cytokine
stock solutions (100 ng/μl) were supplemented with 3%
human serum albumin. All culture media, antibiotics,
and antifungal agents were obtained from Invitrogen
(Carlsbad, CA). Diamide, Ellman's reagent, and DTT were
purchased from Sigma (St. Louis, MO).
Production of TGF-β monomers
TGF-β monomers were prepared by treating 100 μl of
TGF-β at 2 ng/μl with 10 μl 1 M DTT, at 37°C for 20 min-
utes, after which time 10 μl 25% HSA was added to absorb
excessive reducing equivalents. Identical vehicle controls
were prepared without TGF-β in order to determine that
this effect was specific to reduced TGF-β and not an effect
of reducing agents coupled with carrier protein.
Transformed Mink lung epithelial cell TGF-β assay
Mink lung epithelial cells (TMLC cells) transfected with a
plasminogen activator inhibitor-1 promoter linked to a
luciferase reporter system (kind gift of Dr Daniel Rifkin,
NYU) were grown in DMEM high glucose media contain-
ing L-glutamine, pyridoxine hydrochloride, and 110 μg/
ml sodium pyruvate. and supplemented with 10 U/ml
Penicillin G, 10 μg/ml streptomycin G sulfate, 25 ng/ml
Amphotericin B, and 10% heat inactivated FBS in a 5%
CO2 humidified incubator at 37°C. In our laboratory, FBS
independently induced luciferase production, therefore
trypsinized TMLC cells were washed twice in serum-free
media, resuspended to 2.5 × 105 cells/ml in DMEM with-
out FBS and aliquoted (100 μl/well) in a 96 well plate.
The cells were allowed to adhere for 4–6 hours, and then
the media was removed and replaced with cell-free super-
natant of unstimulated or stimulated monocytes or
recombinant protein. Following incubation at 37°C in
5% CO2 for 18–20 hours, the cells were then washed twice
with PBS and lysed with 50 μl cell lysis buffer (Promega,
Madison, WI). The cell lysate (20 μl) was mixed with 90
μL of luciferase assay reagent (Promega) and measured on
a Lumat LB 9507(Berthold, Oak Ridge, TN). Luciferase
values were normalized to that of media alone in recom-
binant protein studies. When supernatants of monocytes
were used, the value was standardized to that of the media
from non-stimulated monocytes.Page 2 of 9
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ELISA kit (R&D Systems) was performed according to
manufacturer's instructions. Briefly, the capture antibody
was diluted to the working concentration in PBS, and was
placed on Costar EIA 96-well plates at 100 μl per well. The
plate was sealed and incubated at room temperature over-
night. The following day each well was aspirated and
washed with wash buffer (0.05% Tween 20 in PBS) for a
total of five washes using an autowasher then blocked for
1 hour at room temperature with PBS containing 5% v/v
Tween 20 and 5% v/v sucrose. Plates were washed, then
100 μl of either isolated protein samples or monocyte
supernatants were added per well. Following incubation
at 37°C for 1 hour, the plates were washed, then incu-
bated with 100 μl of detection antibody for 1 hour at
37°C and washed. Streptavidin-HRP was added to each
well, the plate was covered and protected from light for 20
minutes. The plate was washed as above and 100 μl sub-
strate solution was added to each well and incubated for
an additional 20 minutes at room temperature avoiding
ambient light. The reactions were stopped with 50 μl of 2
N H2SO4 and the optical density was measured at 450 nm
using MRX plate reader (Dynatech Laboratories) and 570
nm for correction.
Western blot and immune detection
Akr cells which have detectable phospho-Smad2/3 activ-
ity in the presence of TGF-β, were plated on costar 12 well
plates at a concentration of 1 × 106 cells/well in serum-free
McCoy's 5A modified media with l-glutamine. Three
hours after treatment the cells were lysed with triple deter-
gent lysis buffer (50 mM Tris-HCl pH 8.0, 0.15 M NaCl,
1% Triton X-100, 0.1% SDS, 5 mg/ml Sodium deoxycho-
late, NaF 1 mM, and Na3VO41 mM) and protein concen-
tration quantitated using the BioRad Assay (Hercules,
CA). Samples prepared from either Akr whole cells lysates
or from recombinant protein were separated on polyacry-
lamide SDS gels, under non-reducing conditions, (15%
for TGF-β, 10% for Phospho-Smad 2) and transferred to
nitrocellulose membrane. Nitrocellulose membranes
were then incubated with either rabbit anti TGF-β (sc-146,
Santa Cruz Biotechnologies), rabbit anti-phospho-Smad2
(cat# 06-829, Upstate Biotechnologies, Lake Placid, NY),
or mouse anti Smad2/3 (cat# S66220, Transduction Lab-
oratories, Louisville KY.) antibodies at a dilution of
1:1500 followed by incubation with the appropriate sec-
ondary antibody and then detection using ECL (Amer-
sham, Arlington Heights, IL). For equal loading
considerations, the membrane used for the anti-phospho-
Smad2 blot was reblotted for Smad2/3.
Reclamation of TGF-β activity with diamide
TGF-β (10 μg) was incubated with either 10 μl of 100 mM
NAC or 5 μl of 100 mM DTT for 15 minutes at room tem-
perature, then 10 μl of 100 mM diamide was added and
samples were incubated for an additional hour. The sam-
ples were diluted with 400 μl PBS containing 1% HSA as
a carrier protein and dialyzed on a 10,000 MWCO Slide-
A-Lyser for 1 hour to remove diamide, which was shown
to have adverse effects on the reporter cells. The dialyzed
sample was then used in the TMLC assay.
Results
NAC and DTT reduce TGF-β production and activation by 
human monocytes but do not reduce TGF-β mRNA 
expression
Since TGF-β can bind receptors on human macrophages
and monocytes in lung tissue [22] and we predict that
TGF-β has a potential role in mediating the development
of pulmonary fibrosis, we sought to understand how TGF-
β activity was regulated by monouclear cells. To measure
active TGF-β, Rifkin, et al. developed a mink lung epithe-
lial cell (TMLC) that has been stably transformed with a
plasminogen activator inhibitor-1 promoter (a common
Smad activated gene) linked to a luciferase reporter sys-
tem. The binding of active TGF-β to TGF-βRI and TGF-βRII
on these cells induces the activation of Smad 2/3, result-
ing in luciferase production. In contrast, latent TGF-β does
not induce luciferase production in this reporter system,
limiting detection to the active TGF-β component, there-
fore we used the TLMC assay to access the activity of TGF-
β produced by human monocytes. Monocytes were
obtained from the Red Cross from healthy volunteers fol-
lowing informed consent and, purified as previously
described [24]. As shown in Figure 1A, monocytes sponta-
neously released latent TGF-β (black bars). GM-CSF and
LPS, but not M-CSF induced the activation of TGF-β by
human monocytes (p < 0.05) (Figure 1A, gray bars).
Although LPS induces monocytes to activate TGF-β [25],
it has not been reported that M-CSF or GM-CSF act simi-
larly. Of these stimuli, LPS resulted in the largest release of
active TGF-β by these monocytes.
We next examined the effect of either NAC or DTT on the
activation of TGF-β by monocytes. Both NAC and DTT
reduced the activity of TGF-β from untreated monocytes
(Figure 1B) or monocytes treated with either M-CSF (Fig-
ure 1C), GM-CSF(Figure 1D), or LPS (Figure 1E).
We then determined if the reduction of TGF-β production
by NAC and DTT in monocytes was due to inhibition of
gene transcription. The treated monocytes were then sub-
jected to real time PCR analysis to examine TGF-β mRNA
levels. As shown in Figure 2 the addition of NAC or low
concentrations of DTT had no effect on the TGF-β mRNA
levels. However, TGF-β mRNA expression was slightly
decreased only by the addition of the 10 mM DTT (Figure
2).Page 3 of 9
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TGF-β activity produced by monocytes is decreased by NAC and DTTFigure 1
TGF-β activity produced by monocytes is decreased by NAC and DTT. Human monocytes (5 × 106/condition) were 
incubated in media alone or with M-CSF (100 ng/ml), GM-CSF (100 ng/ml) or LPS (100 ng/ml) for 18 hours. (A) Cell-free 
supernatants were harvested and analyzed by TMLC assay for active TGF-β (Grey bars) and compared against total TGF-β pro-
duced (Black bars). M-CSF, GM-CSF and LPS induce more active TGF-β from monocytes than that induced by incubation with 
media alone, p = 0.06 for M-CSF, p < 0.05 for GM-CSF and p < 0.01 for LPS. These data are composite of six independent 
studies. These same conditions are shown titrated against increasing concentrations of NAC and DTT, non stimulated (B) or 
incubated with M-CSF (C), GM-CSF (D) or LPS (E). After incubation, cell-free supernatants were evaluated for TGF-β by 
TMLC assay and were expressed as percent control of samples treated without NAC and DTT. NAC (20 mM) and DTT (both 
1 and 10 mM) reduced TGF-β activation and production by all the stimulating agents and from cells left not stimulated (p < 
0.01 versus samples not treated with NAC or DTT). The data shown are representative of four measurements each from six 
independent studies.
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To study the relationship between the redox state of TGF-
β and its activity we incubated recombinant TGF-β with
either NAC or DTT. The treated TGF-β was dialyzed
against PBS to remove the NAC and DTT trace then
assayed for activity using the TMLC assay. We found that
only 20 mM NAC whereas both DTT concentrations (10
mM and 1 mM) were able to reduced TGF-β activity meas-
ured by TMLC luciferase assay (Figure 3A) (p < 0.001 for
active TGF-β1 incubated with NAC (20 mM) and DTT (10
mM) versus active TGF-β1 (1 ng/ml) alone). We further
confirmed our observations by incubating the reduced
TGF-β with the oxidizing agent diamide. We found that
diamide treatment restored the detection of TGF-β from
NAC and DTT-treated samples (Figure 3A).
We hypothesized that NAC or DTT reduced the biological
activity of purified TGF-β by reducing TGF-β homodimers
to monomers. We therefore analyzed the generation of
monomers from the active human (25 kDa) homodimers
with either NAC or DTT in the absence or presence of
diamide. We detected TGF-β monomers with the apparent
molecular weight of 12.5 kDa in samples treated alone
with either NAC or DTT by Western blot analysis (Figure
3B) suggesting that these reducing agents promoted the
formation of TGF-β monomers. Notably, addition of
diamide restored detection of the 25 kD isoform of TGF-β.
Activity of purified TGF-β NAC is dependent on Redox stateFigure 3
Activity of purified TGF-β NAC is dependent on 
Redox state. Purified active TGF-β (R&D Systems) was 
treated with either NAC or DTT as described, was then 
incubated in the absence or presence of 10 mM diamide for 
two hours at 37°C. Samples were dialyzed for two hours 
then either (A) incubated with TMLC cells to measured luci-
ferase production or (B) separated by polyacrylamide gel 
electrophoresis and subjected to western blot analysis TGF-
β. Data represents percent of control ± standard error 
where control is TGF-β sample untreated (p < 0.05 for NAC 
2 mM and 10 mM versus TGF-β alone). Diamide restored 
activity levels to that of TGF-β alone (p > 0.05 of TGF-β 
alone versus TGF-β + NAC (20 mM) or TGF-β + DTT (10 
mM) + diamide). Recombinant human TGF-β migrated as a 
~25 kD protein that was reduced to a ~12.5 kD protein by 
the addition of NAC or DTT. Data shown in (B) is a repre-
sentative of six independent experiments.
NAC and DTT do not consistently reduce TGF-β mRNA synthesis from human m ocytesFigure 2
NAC and DTT do not consistently reduce TGF-β 
mRNA synthesis from human monocytes. Monocytes 
(10 × 106 per condition) were treated with 2 mM NAC, 20 
mM NAC, 1 mM DTT, or 10 mM DTT and incubated for 24 
hours. Data points represent fold induction over non-stimu-
lated; mean is represented by horizontal bar. Only DTT 10 
mM reduced TGF-β mRNA versus non-stimulated control 
cells (p < 0.05) other conditions were not significantly differ-
ent statistically. This data represents three independent stud-
ies.Page 5 of 9
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β1
Since we could generate monomeric forms of TGF-β,
which failed to be recognized by our reporter assay sys-
tem, we were interested to understand the biological func-
tion of this protein. We therefore hypothesized that TGF-
β monomers would act as competitive inhibitors of the
cellular activation induced by TGF-β homodimers. TGF-β
monomers were unable to induce luciferase production in
the TMLC assay at concentrations below 1 nM (Figure
4A). Notably higher concentrations exceeding 1 nM
retained some agonist activity measured by TMLC assay.
Compared to dimeric TGF-β which was capable of elicit-
ing an effect at concentrations below 0.001 nM, the level
of activation by the TGF-β monomers was 1000-fold less
active (Figure 4A). To examine whether the monomeric
TGF-β form could act as a competitive inhibitor, increas-
ing concentrations of monomeric TGF-β was incubated
with the homodimeric isoform. As predicted, TGF-β mon-
omers generated by treating active TGF-β with DTT,
reduced luciferase production in TMLC cells when used in
50-fold excess to active TGF-β (Figure 4B).
We further confirmed that the inhibitory effect of the
monomeric TGF-β was modulated within the cell. Since
Smad2 is the downstream activator of TGF-β stimulation,
we examined whether the monomeric TGF-β form could
prevent the activation of Smad2. As shown in Figure 4C,
the addition of monomeric TGF-β alone to Akr epithelial
cells failed to activate Smad2 when compared to cells
treated with the homodimeric form. Notably, incubation
with both the dimer and 50-fold excess of monomer TGF-
β resulted in a reduction of Smad 2/3 activation by mon-
omeric TGF-β to dimeric TGF-β (Figure 4C). Of note, DTT-
treated monomers were extensively washed, and
quenched with Human Serum Albumin prior to using in
competitive inhibitor studies to reduce the likelihood that
inhibitory activity reflected residual DTT left in the cul-
ture.
Discussion
Latent TGF-β is primarily regulated by post-translational
activation of TGF-β from LAP [3]. However, the mecha-
nism of TGF-β activation in human cells is incompletely
understood. Interestingly, immunohistochemical analysis
of pathological tissue from humans with pulmonary
fibrosis shows that TGF-β localizes to areas with increased
amounts of macrophages in the lung [22,23]. To define
the mechanism used by these cells to activate TGF-β, we
found that the addition of GM-CSF or LPS, but not M-CSF
to these monocytes induced the activation of TGF-β. Inter-
estingly, NAC and DTT significantly lessened TGF-β pro-
duced by these monocytes, irrespective of whether growth
factors or LPS was added. To investigate the mechanism
involved, we initially found that NAC or DTT did not con-
sistently decrease mRNA expression of TGF-β, suggesting
that the level of regulation was post-transcriptional. Sub-
sequently, we realized that NAC and DTT also reduced the
activity of recombinant human TGF-β in a cell-free system
and hypothesized that these agents lessened TGF-β activ-
ity by reducing disulfide bonds of the active homodimers.
We next found that treatment of active TGF-β with NAC or
DTT reduced the size of detectable purified TGF-β from 25
kD to 12.5 kD. Diamide restored detection of the 25 kD
isoform of TGF-β in the presence of NAC and DTT and
also restored the biological activity of TGF-β. Next, we
wondered if these 12.5 kD TGF-β monomers would com-
petitively inhibit cellular activation induced by active
TGF-β homodimers. If used in 50-fold molar excess, TGF-
β monomers inhibited cellular activation by active TGF-β
homodimers assayed by either a luciferase-based reporter
system or by assessing Smad 2 activation. Thus, TGF-β
TGF-β treated with DTT functions as competitive inhibitorsFigure 4
TGF-β treated with DTT functions as competitive 
inhibitors. (A) Comparison of the luciferase activity 
released by TMLC cells that were incubated with recom-
binant human TGF-β (°) or DTT-treated TGF-β (•). Recom-
binant TGF-β is activate below 25 pM, while the DTT-
treated TGF-β only showed activity at 5 nM. (B) TMLC cells 
(1.0 × 104 TMLC cells/well) were incubated with recom-
binant human TGF-β at 50 pM and increasing concentrations 
of DTT-treated TGF-β. Competitive agonist effect of DTT-
treated TGF-β was apparent at ~100 fold higher concentra-
tion. The data shown are representative of three independ-
ent studies done in quadruplicate. (C) Mouse epithelial Akr 
cells (1.0 × 106 cells/condition) containing TGF-β receptors, 
were treated with 5 ng/ml of rhTGF-β and phosphorylated 
SMAD2/3 was measured by western blotting. The blots were 
quantitated by densitometry (bar graph) and 50 ng/ml mono-
meric TGF-β lowers the impact of the dimeric TGF-β (p < 
0.01 vs non stimulated, p = 0.127 vs dimer treated). The data 
are representative of eleven independent studies. Error bars 
represent the standard error of the mean.Page 6 of 9
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the biological effects of active TGF-β.
The production and activation of TGF-β plays an impor-
tant role in regulating the acute and chronic phases of tis-
sue injury. TGF-β is a growth factor that plays an
important role in the regulation of the inflammatory
response [24], and in fact, transgenic animals lacking
TGF-β die of overwhelming inflammation in utero or at
young ages[25,26]. In addition to anti-inflammatory
properties, TGF-β promotes fibrosis as part of altered tis-
sue repair [27,28]. For example, in pulmonary fibrosis,
TGF-β is found in the lung and the elevation in levels of
TGF-β correlate with the extent of fibrosis. In animal mod-
els of pulmonary fibrosis, administering antibodies to
TGF-β or blocking signal transduction modulated by
active TGF-β by over-expressing the inhibitory Smad-7
blocks fibrosis [13-15]. Thus, defining the specific mecha-
nisms regulating the production and activation of TGF-β
may have therapeutic opportunities to help patients with
fibrotic diseases.
As opposed to recent trends using molecular targeted ther-
apy for cancer, most treatments for patients with inflam-
matory or fibrotic diseases have not used similar
strategies. Currently, well-defined molecular or cellular
targets are lacking in patients with fibrosis, although TGF-
β has been found to play a causal role. Our data suggests
that agents like NAC and DTT decrease the biological
function of TGF-β and liberate TGF-β monomers. Modify-
ing active TGF-β homodimers to inactive monomers
results in loss of biological activity, and the generation of
a competitive TGF-β receptor agonist. This new therapeu-
tic opportunity links to other strategies that interfere with
the production and activation of TGF-β including decorin
[28], antiplasmin [29] or other cytokines like interferon-γ
[30].
Conclusion
Based on our results, NAC and DTT reduce the biological
activity of TGF-β after activation. Since activation of TGF-
β is thought to be the most powerful regulator of the bio-
logical activity of TGF-β, reducing the biological activity of
TGF-β after activation heightens the therapeutic opportu-
nity to treat patients with tissue fibrosis. These data also
provide a tentative mechanism for reducing agents like
NAC as treatment for pulmonary fibrosis [32-34]. One
potential mechanism for the effect of NAC in these studies
may be reduction in the biological activity of TGF-β,
reducing fibrosis. In this paper, we suggest that TGF-β
monomers resulting from treatment with NAC and DTT
may compete with TGF-β dimers for TGF-β receptors.
Thus, altering the reduction-oxidation state of the envi-
ronment may influence the function of TGF-β. We believe
that understanding the molecular regulation of TGF-β
activation and recognition may provide opportunity to
intercede on this process.
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Animation clip showing the active form of TGF-β, a dimer, binding to it's 
receptor RII, then crosslinking with RI to initiate signaling.




Animation clip showing reducing agents creating TGF-β monomers which 
interfere with signaling.




TGF-β mRNA quantikine kit to quantify TGF-β1 mRNA produced my 
monocytes treated with growth factors and reducing ageants. Figure 
Legend: NAC does not affect TGF-β mRNA synthesis from human mono-
cytes treated with Growth Factors. Monocytes (5 × 106/condition) were 
treated with M-CSF(100 ng/ml), GM-CSF(100 ng/ml), and LPS (100 
ng/ml) in the presence or absence of 20 mM NAC. TGF-β was measured 
using specific mRNA quantikine kit. Method: 5 × 106 Monocytes per con-
dition, treated with M-CSF, GM-CSF, or LPS(all 100 ng/ml.) In the 
presence or absence of 20 mM NAC. Results: No statistaical difference 
between in mRNA production, between any condition.
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Additional File 4
Ellman's Reagent to quantify Thiol reduction by NAC, DTT, and oxi-
dation by Diamide. Figure Legend: DTT and NAC increase detection 
by Ellman's reagent. DTT (0.01, 0.05, 0.1, 0.5, 1.0, 5, 10 mM) and 
NAC (0.01, 0.05, 0.1, 0.5, 1.0, 5, 10 mM) were added to DTNB. The 
lowest concentration of NAC that was detectable to reduce the disulfide 
bond in DTNB was 2.0 × 10-9 M, well below what was used in our exper-
iments with TGF-β. To these concentrations, increasing amounts of 
Diamide (0.1, 0.2, 1.0, 2.0, and 10 mM) were added and the ability to 
reoxidize DTNB was noted as absorbance at 410 nm. 10 mM diamide 
was not able to reoxidize DTNB at the highest concentrations of DTT, but 
was able to reoxidize 10 mM NAC treated DTNB. These data represent 
four redundant measurements from 3 independent studies. The line for 
1.0 was left off the graph for simplicity of viewing. Method: Ellman's rea-
gent (3,3'-dithio-bis(6-nitrobenzoic acid), DTNB) at 1 mmol in PBS 
with 10 mM EDTA was placed in a 96 well plate at 100 μl per well. Iden-
tical plates were made for measuring the reducing power of NAC and DTT 
under physiological conditions. Concentrations of 0, 0.01, 0.05, 0.1, 0.5, 
1.0, 5, and 10 mM NAC and DTT were titrated against 0, 0.1, 0.2, 1.0, 
2.0, and 10 mM diamide. The absorbance was checked on an ELx 808 at 
410 nm using 570 nm as a correction for the absorbance of the plates. 
Results: NAC and DTT reduce disulfide bonds which is reversed by 
diamide. To confirm that the concentrations of NAC and DTT we used 
in these studies were sufficient to reduce disulfide bonds, we used Ellman's 
reagent to detect formation of free sulfhydryl residues. Treatment of Ell-
man's reagent with NAC or DTT induced a 0.98 ± 0.02 and 1.6 ± 0.1 
molar ratio increase in free sulfhydryl groups, respectively. Diamide was 
able to re-oxidize the disulfide bond at equimolar concentrations of the 
reducing agents, to form a colorless compound. Complete oxidation was 
noted at 10-fold excess of diamide to NAC and all but the highest concen-
tration of DTT.
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